CO6260055A2 - PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAME - Google Patents
PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAMEInfo
- Publication number
- CO6260055A2 CO6260055A2 CO10020543A CO10020543A CO6260055A2 CO 6260055 A2 CO6260055 A2 CO 6260055A2 CO 10020543 A CO10020543 A CO 10020543A CO 10020543 A CO10020543 A CO 10020543A CO 6260055 A2 CO6260055 A2 CO 6260055A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- calcium channel
- silicon dioxide
- colloidal silicon
- channel antagonist
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con una formulación de formas de dosificación sólidas que comprende una cantidad terapéuticamente efectiva de un antagonista del canal de calcio de tipo dihidropiridina como la lecarnidipina o sal del mismo, en combinación con dióxido de silicio coloidal tal como AerosilTM para aumentar la biodisponibilidad y mejorar la solubilidad, y un proceso para la preparación de la formulación mediante la granulación en húmedo. 1.- Una composición farmacéutica para la administración oral caracterizada porque comprende un antagonista del canal de calcio de tipo dihidropiridina y en particular la lercanidipina o una sal farmacéuticamente aceptable, derivado y polimorfo del mismo, como un ingrediente activo, y una cantidad efectiva de un dióxido de silicio coloidal, como AerosilTM para aumentar la biodisponibilidad y/o mejorar la solubilidad. 2.- La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque dicho dióxido de silicio coloidal es AerosilTM. 3.- La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la relación en peso de dicho antagonista del canal de calcio de tipo dihidropiridina o una sal farmacéuticamente aceptable del mismo al dióxido de silicio coloidal es preferiblemente de 10/1 a 1/60. 4.- La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque esta comprende aproximadamente de 0.5% a 30%, más preferiblemente de 3% a 25% y más preferiblemente de 5% a 10% en peso de dicho antagonista del canal de calcio de tipo dihidropiridina o una sal farmacéutica aceptable del mismo.The present invention relates to a formulation of solid dosage forms comprising a therapeutically effective amount of a dihydropyridine calcium channel antagonist such as lecarnidipine or salt thereof, in combination with colloidal silicon dioxide such as Aerosil ™ to increase the bioavailability and improve solubility, and a process for the preparation of the formulation by wet granulation. 1. A pharmaceutical composition for oral administration characterized in that it comprises a calcium channel antagonist of the dihydropyridine type and in particular lercanidipine or a pharmaceutically acceptable salt, derivative and polymorph thereof, as an active ingredient, and an effective amount of a colloidal silicon dioxide, such as AerosilTM to increase bioavailability and / or improve solubility. 2. The pharmaceutical composition according to claim 1, characterized in that said colloidal silicon dioxide is Aerosil ™. 3. The pharmaceutical composition according to claim 1, characterized in that the weight ratio of said dihydropyridine calcium channel antagonist or a pharmaceutically acceptable salt thereof to colloidal silicon dioxide is preferably 10/1 to 1 / 60 4. The pharmaceutical composition according to claim 1, characterized in that it comprises approximately 0.5% to 30%, more preferably 3% to 25% and more preferably 5% to 10% by weight of said channel antagonist. dihydropyridine type calcium or an acceptable pharmaceutical salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CO10020543A CO6260055A2 (en) | 2010-02-22 | 2010-02-22 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CO10020543A CO6260055A2 (en) | 2010-02-22 | 2010-02-22 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260055A2 true CO6260055A2 (en) | 2011-03-22 |
Family
ID=43806576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10020543A CO6260055A2 (en) | 2010-02-22 | 2010-02-22 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| CO (1) | CO6260055A2 (en) |
-
2010
- 2010-02-22 CO CO10020543A patent/CO6260055A2/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP109984A (en) | IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING DIHYDROPIRIDINE, ANTAGONIST OF THE CALCIUM CHANNEL AND THE METHOD FOR PREPARATION | |
| ZA201608614B (en) | Solid oral pharmaceutical compositions for isoxazoline compounds | |
| CR11137A (en) | HEART PROSTETIC VALVES | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| CL2020000747A1 (en) | Niraparib formulations. | |
| CO6220902A2 (en) | VALGANCICLOVIR POWDER FORMULATION | |
| WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| UA116334C2 (en) | SOLID FORMS OF BENDAMUSTINE DOSAGE | |
| TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| BRPI0925315B8 (en) | pharmaceutical composition of fixed dosage, oral, solid, stable in the form of a monolayer tablet, process for its preparation and use of irbesartan and amlodipine besylate | |
| BR112013026361A2 (en) | glycoside derivatives and uses thereof | |
| BR112015014433A2 (en) | tricyclic compounds | |
| CO6640318A2 (en) | Oral dosage forms of bendamustine | |
| UY30847A1 (en) | USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS | |
| CR20120432A (en) | SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINO BESYLATE AND ITS PREPARATION | |
| MA32722B1 (en) | GALENIC FORMULATION COMPRISING ALISKIRENE AND ASSOCIATED PREPARATION METHOD BY FUSION-EXTRUSION GRANULATION | |
| CO6260055A2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIGONIST OF THE CALCIUM CHANNEL OF TYPE DIHYDROPIRIDINE AND METHOD FOR THE PREPARATION OF THE SAME | |
| WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
| GR1008819B (en) | Pharmaceutical composition comprising atomoxetine and method for the preparation thereof | |
| TR200802061A2 (en) | Pharmaceutical formulation containing highly active ingredient. | |
| GR1008821B (en) | Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof | |
| JP2016527284A5 (en) | ||
| EA201500366A1 (en) | APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR | |
| IN2013MU02286A (en) | ||
| MY150480A (en) | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |